We've changed the way you complete courses

In response to user feedback we have simplified the way courses can be completed.

Until now you needed to complete the topics and modules in order, from start to finish. But from today you can complete them in any order you wish.

Just visit any topic that interests you, and when you are ready mark it as completed by clicking the green 'Mark complete' button at the bottom of the page.

Once you have completed all of the topics in a module an assessment will be provided for you.

Complete all the assessments to finish the course.

Thanks, I've got it! X

Studies, such as those in Scandinavia, showed that if you add a GLP-1 receptor agonist, such as liraglutide to intensive insulin therapy to those with type 1 diabetes; there is an advantage in lowering HbA1c, lowering body weight and lowering insulin dose. However, the caveat of these studies is that they were quite short (6 months). The advantage of the ADJUNCT studies is that they lasted up to one year.

Interesting studies are the studies where a GLP-1 receptor agonist was added to insulin in people with type 1 diabetes. Quite a few investigator-driven studies were performed, especially in Scandinavia, where they showed that if you add a GLP-1 receptor agonist, like liraglutide, to intensive insulin therapy in people with type 1 diabetes, there is an advantage in lowering HbA1c, in lowering body weight and in lowering insulin dose for those taking liraglutide. Now the caveat in all of these studies is that they were quite short, namely six months. And so, interesting studies are the ADJUNCT studies by the company Novo Nordisk themselves, where we looked, again in a double-blinded way, at the effect of liraglutide, compared with placebo, with different doses of liraglutide on HbA1c, weight and insulin dose in people with type 1 diabetes. But the advantage of the ADJUNCT studies was that they lasted more than six months, even up to one year. And what the ADJUNCT studies showed was that, although we saw a dose-dependent lowering in HbA1c in the people treated with liraglutide compared with placebo up to six months, we saw that this effect waned by one year. And at one year, you only had a very small difference between liraglutide-treated patients and placebo-treated patients on HbA1c. The effect on weight was dose-dependent again and here we did see by one year an advantage in weight loss for liraglutide-treated patients compared with placebo-treated patients. And in all of this, the HbA1c lowering and the weight lowering was also accompanied by less insulin dose in the people treated with the liraglutide. Now the big point of the ADJUNCT therapies was that we saw this effect by six months, but by one year it started to wane, suggesting that the effect of liraglutide is not sustainable.
Play the audio to learn more
Select image for larger view
Select image for larger view
Select image for larger view

Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, Linder M, Bode B; ADJUNCT ONE Investigators. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. 2016 Oct;39(10):1702-10
http://www.ncbi.nlm.nih.gov/pubmed/27506222